When did Ocular Therapeutix go public?
July 25, 2014
Ocular Therapeutix Prices Initial Public Offering All of the shares in the offering are being sold by Ocular. Ocular’s common stock has been approved for listing on the NASDAQ Global Market and is expected to begin trading under the ticker symbol “OCUL” on July 25, 2014.
Why is ocular therapeutix stock dropping?
Investing.com — Shares of Ocular Therapeutix Inc (NASDAQ:OCUL) tumbled over 34% Friday after the failure of its Phase 2 clinical trial of OTX-CSI to treat dry eye disease.
Is OCUL stock a buy?
A yield of 8.57% also means 8.57 cents of earnings for $1 of investment….Momentum Scorecard. More Info.
| Zacks Rank | Definition | Annualized Return |
|---|---|---|
| 1 | Strong Buy | 25.42% |
| 2 | Buy | 19.05% |
| 3 | Hold | 10.68% |
| 4 | Sell | 6.41% |
What is Ocular Therapeutix?
Ocular Therapeutix’s first commercial drug product, DEXTENZA® (dexamethasone ophthalmic insert) 0.4 mg, is an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis.
What is the meaning of OCUL?
eye
Ocul- is a combining form used like a prefix meaning “eye” or “ocular,” a term that means “of or relating to the eye.” It occurs in a few medical and scientific terms. Ocul- comes from the Latin oculus, meaning “eye.” See more about oculus at our entry for the word.
Who owns Ocular Therapeutix?
Opaleye Management, Inc.
Ownership Ocular Therapeutix Inc. Opaleye Management, Inc.
How many employees does Ocular Therapeutix have?
Latest Updates
| Employees (est.) (Mar 2019) | 167 | (+41%) |
|---|---|---|
| Job Openings | 19 | |
| Revenue (FY, 2020) | $17.4 M | (+312%) |
| Share Price (Nov 2021) | $7 | (-7%) |
| Cybersecurity rating | B | More |
What is Oculonasal?
Filters. Pertaining to the eyes and nose. An oculonasal discharge. adjective.
What is Oculomycosis?
(ŏk″ū-lō-mī-kō′sĭs) [″ + Gr. mykes, fungus, + osis, condition] Any disease of the eye or its parts caused by fungus.
When was Dextenza FDA approved?
Development Timeline for Dextenza
| Date | Article |
|---|---|
| Dec 3, 2018 | Approval FDA Approves Dextenza (dexamethasone ophthalmic insert) for the Treatment of Ocular Pain Following Ophthalmic Surgery |
| Jun 29, 2018 | Ocular Therapeutix Announces NDA Resubmission of Dextenza |
What is Dextenza?
Dextenza is a revolutionary new option to treat post-surgical symptoms and reduce the number of eye drops needed following cataract surgery. Dextenza is a corticosteroid that provides extended time-release of steroids into the eye, developed by Ocular Therapeutix.